Payment overview · 2025
General Payments
$178.32
9 reported records · 6 companies
Healthcare provider profile · identity verified
Alonzo James Davis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOREHEAD CITY, NC · NPI 1114001583
Verified facts
What the public records show
CMS Open Payments records show Alonzo James Davis, MD received $178.32 in general payments during 2025 across 9 reported records.
Dexcom, Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.07 | 22.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.19 | 19.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.78 | 18.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.86 | 15.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.09 | 13.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.33 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $178.32 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 71 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 89 |
| Eliquis | Apixaban | 266 | 53 |
| Lisinopril | Lisinopril | 247 | 68 |
| Losartan Potassium | Losartan Potassium | 244 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 59 |
| Gabapentin | Gabapentin | 204 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 183 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 48 |
| Furosemide | Furosemide | 160 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 40 |
| Omeprazole | Omeprazole | 147 | 47 |
| Sertraline Hcl | Sertraline Hcl | 129 | 37 |
| Alprazolam | Alprazolam | 128 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 38 |
| Metformin Hcl | Metformin Hcl | 120 | 42 |
| Trazodone Hcl | Trazodone Hcl | 108 | 29 |
| Prednisone | Prednisone | 106 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 21 |
| Celecoxib | Celecoxib | 99 | 29 |
| Metformin Hcl Er | Metformin Hcl | 96 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 30 |
| Meloxicam | Meloxicam | 89 | 24 |
| Potassium Chloride | Potassium Chloride | 87 | 28 |
| Simvastatin | Simvastatin | 85 | 22 |
| Donepezil Hcl | Donepezil Hcl | 82 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 24 |
| Lorazepam | Lorazepam | 78 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 76 | 24 |
| Jardiance | Empagliflozin | 76 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 21 |
| Glimepiride | Glimepiride | 72 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 30 |
| Synthroid | Levothyroxine Sodium | 71 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 22 |
| Alendronate Sodium | Alendronate Sodium | 66 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 18 |
| Dutasteride | Dutasteride | 62 | 15 |
| Montelukast Sodium | Montelukast Sodium | 62 | 18 |
| Ozempic | Semaglutide | 62 | 11 |
| Temazepam | Temazepam | 60 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 15 |
| Spironolactone | Spironolactone | 57 | 14 |
| Chlorthalidone | Chlorthalidone | 56 | 18 |
| Meclizine Hcl | Meclizine Hcl | 53 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Carvedilol | Carvedilol | 49 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 12 |
| Diazepam | Diazepam | 45 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | 12 |
| Mirtazapine | Mirtazapine | 33 | 14 |
| Risperidone | Risperidone | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 23 |
| Tramadol Hcl | Tramadol Hcl | 30 | 15 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 14 |
| Estradiol | Estradiol | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 26 | 20 |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 11 |
| Finasteride | Finasteride | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Valacyclovir | Valacyclovir Hcl | 22 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 21 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $178.32 · 9 records | Dexcom, Inc. | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, OTEZLA, REPATHA, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error